Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives
References (0)
Cited by (147)
Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review
2018, Clinical Gastroenterology and Hepatology5-Aminosalicylic acid dependency in Crohn's disease: A Danish Crohn Colitis Database study
2010, Journal of Crohn's and ColitisCitation Excerpt :Contrary to this, the role of 5-ASA in Crohn's disease (CD) is conflicting. Several trials comparing effect of 5-ASA to placebo have been done with divergent results.3–8 A meta-analysis investigating efficacy of 5-ASA in treatment of active CD and 2 meta-analyses focused on maintenance therapy failed to prove its efficacy.9–11
The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management
2010, Journal of Crohn's and ColitisCitation Excerpt :Details of the action, pharmacology, dosage, side effects and monitoring of aminosalicylates, steroids, thiopurines, methotrexate and anti-TNF therapy are in the Active Disease section. Randomized trials designed to evaluate the efficacy of aminosalicylates (5-ASA) for maintaining medically induced remission are shown in Table 6.1.124–134 No additional study to evaluate the efficacy of 5-ASA for this indication has been published in Crohn's disease since 2001.
News and controversy in inflammatory bowel disease treatment
2009, Italian Journal of MedicineTwenty-five years of biologicals in IBD: What´s all the hype about?
2021, Journal of Internal Medicine